The science behind the therapy developed for treating Pulmonary Fibrosis in Long Haul COVID patients, VL-PX10 and VL-P22.

VL-PX10 and VL-P22 are a first-in-class combination therapy for Pulmonary Fibrosis in Long Haul COVID patients. This proprietary therapy consists of human Umbilical Cord Mesenchymal Stem Cell Exosomes, Mesenchymal Stem Cells, and their biomaterials.

*Combination therapy is the method of using two or more therapies to treat one disease.


Umbilical Cord Tissue MSC

Exosomes contain lipids, proteins, and nucleic acids. With these materials, exosomes play a critical role in tissue regeneration and environmental regulation through paracrine signaling. Paracrine signaling is a form of intracellular signaling in which the exosome produces a signal to induce changes in nearby cells, altering the behavior of those cells to invoke a healing response.


Umbilical Cord Tissue Stem Cells and Biomaterials

The umbilical cord contains the biomaterials to orchestrate the integration of complex biological and molecular events, which include inflammation, proliferation, and migration, and accelerate re-epithelization. The MSCs secrete bioactive molecules, which are both immunomodulatory and trophic factor modulatory by nature, supporting fibrotic tissue regeneration.

VL-PX10 and VL-P22 have shown to be an effective therapy in patients with Acute Respiratory Disease from COVID-19.

How VL-PX10 and VL-P22 Helped During COVID-19

COVID was an extraordinarily challenging event for all. Companies and individuals stepped up to help out however they could.

Vitti Labs™ teamed up with Trinitas Hospital to offer a treatment to patients in need.

“Trinitas was among the first to use a stem cell therapy developed by Vitti Labs™.”

How VL-PX10 and VL-P22 are Helping Now

Today VL-PX10 and VL-P22 are in Phase 2 Human Clinical Trials as a potential therapy for Pulmonary Fibrosis in Long Haul COVID patients.